[go: up one dir, main page]

MA44922B1 - Anticorps - Google Patents

Anticorps

Info

Publication number
MA44922B1
MA44922B1 MA44922A MA44922A MA44922B1 MA 44922 B1 MA44922 B1 MA 44922B1 MA 44922 A MA44922 A MA 44922A MA 44922 A MA44922 A MA 44922A MA 44922 B1 MA44922 B1 MA 44922B1
Authority
MA
Morocco
Prior art keywords
antibody
binding
fragment
present
dna
Prior art date
Application number
MA44922A
Other languages
English (en)
Other versions
MA44922A1 (fr
Inventor
Graham Craggs
Karine Jeannine Madeleine Herve
Diane Marshall
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44922(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA44922A1 publication Critical patent/MA44922A1/fr
Publication of MA44922B1 publication Critical patent/MA44922B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne un anticorps anti-csf-1r et des fragments de liaison associés, de l'adn codant pour celui-ci, des cellules hôtes comportant ledit adn et des méthodes d'expression de l'anticorps ou d'un fragment de liaison dans une cellule hôte. La présente invention s'étend également à des compositions pharmaceutiques comprenant l'anticorps ou un fragment de liaison associé, et l'utilisation de l'anticorps, du fragment de liaison et des compositions les comprenant dans un traitement.
MA44922A 2013-08-30 2014-08-26 Anticorps MA44922B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315487.7A GB201315487D0 (en) 2013-08-30 2013-08-30 Antibodies
PCT/EP2014/068050 WO2015028455A1 (fr) 2013-08-30 2014-08-26 Anticorps

Publications (2)

Publication Number Publication Date
MA44922A1 MA44922A1 (fr) 2019-08-30
MA44922B1 true MA44922B1 (fr) 2020-06-30

Family

ID=49397073

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44922A MA44922B1 (fr) 2013-08-30 2014-08-26 Anticorps
MA38930A MA38930A1 (fr) 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA38930A MA38930A1 (fr) 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)

Country Status (39)

Country Link
US (2) US9908939B2 (fr)
EP (3) EP3038643B1 (fr)
JP (3) JP6632075B2 (fr)
KR (1) KR102303130B1 (fr)
CN (2) CN112321711B (fr)
AR (1) AR097464A1 (fr)
AU (1) AU2014314304B2 (fr)
BR (1) BR112016004324B1 (fr)
CA (1) CA2922240C (fr)
CL (1) CL2016000438A1 (fr)
CY (1) CY1121964T1 (fr)
DK (2) DK3549599T5 (fr)
EA (1) EA036255B1 (fr)
ES (2) ES2733735T3 (fr)
FI (1) FI3549599T3 (fr)
GB (1) GB201315487D0 (fr)
HR (2) HRP20191051T1 (fr)
HU (2) HUE045672T2 (fr)
IL (1) IL244043B (fr)
LT (2) LT3038643T (fr)
MA (2) MA44922B1 (fr)
MX (1) MX372950B (fr)
MY (1) MY172484A (fr)
NZ (1) NZ717399A (fr)
PE (2) PE20201067A1 (fr)
PH (1) PH12016500275B1 (fr)
PL (2) PL3038643T3 (fr)
PT (2) PT3549599T (fr)
RS (2) RS64784B1 (fr)
SG (1) SG11201601151PA (fr)
SI (2) SI3549599T1 (fr)
SM (2) SMT202300409T1 (fr)
TN (1) TN2016000067A1 (fr)
TR (1) TR201909478T4 (fr)
TW (1) TWI531582B (fr)
UA (1) UA118354C2 (fr)
UY (1) UY35718A (fr)
WO (1) WO2015028455A1 (fr)
ZA (1) ZA201601437B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
CN107660152B (zh) * 2015-05-27 2021-11-05 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
JP2018516933A (ja) * 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP4467565A3 (fr) 2016-12-21 2025-03-12 Amgen Inc. Formulations d'anticorps anti-tnf alpha
WO2018183366A1 (fr) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Polythérapies d'anticorps csf-1r ou csf-1 et thérapie reposant sur des lymphocytes t
EP3624848A1 (fr) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Polythérapies
GB201803226D0 (en) 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN108948198B (zh) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其应用
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
US12043668B2 (en) 2018-12-13 2024-07-23 Development Center For Biotechnology Anti-human CSF-1R antibody and uses thereof
WO2020232051A1 (fr) * 2019-05-15 2020-11-19 Biosion Inc. Anticorps se liant à csf-1r et son utilisation
KR20220123004A (ko) * 2019-12-09 2022-09-05 신닥스 파마슈티컬스, 인크. 만성 이식편 대 숙주 질환의 치료를 위한 항체
CA3162403A1 (fr) * 2019-12-24 2021-07-01 Fangyong Du Molecules anti-csf1r et utilisation correspondante
AU2024274397A1 (en) 2023-05-17 2025-11-13 Syndax Pharmaceuticals, Inc. Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
WO2025024272A1 (fr) 2023-07-23 2025-01-30 Incyte Corporation Méthodes de traitement d'une maladie du greffon contre l'hôte chronique à l'aide d'un anticorps anti-récepteur du facteur 1 de stimulation des colonies
US20250325664A1 (en) 2024-04-22 2025-10-23 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
CN101802008B (zh) * 2007-08-21 2015-04-01 安美基公司 人类c-fms抗原结合蛋白
CA2700714C (fr) 2007-09-26 2018-09-11 Ucb Pharma S.A. Fusions d'anticorps a double specificite
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2009224955B2 (en) 2008-03-14 2012-08-09 Transgene S.A. Antibody against the CSF-1 R
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
EP2475682B1 (fr) 2009-09-10 2018-01-31 UCB Biopharma SPRL Anticorps multivalents
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
PT2949670T (pt) * 2009-12-10 2019-05-20 Hoffmann La Roche Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2011107553A1 (fr) * 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Anticorps dirigés contre le csf-1r humain et utilisations associées
CA2789071C (fr) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CN107011438B (zh) * 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
RU2658603C2 (ru) * 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
JP2020005652A (ja) 2020-01-16
MA44922A1 (fr) 2019-08-30
PL3549599T3 (pl) 2024-03-04
DK3549599T5 (da) 2024-09-02
TR201909478T4 (tr) 2019-07-22
RS64784B1 (sr) 2023-11-30
MX372950B (es) 2020-04-03
PT3038643T (pt) 2019-07-25
AR097464A1 (es) 2016-03-16
CA2922240A1 (fr) 2015-03-05
LT3038643T (lt) 2019-07-25
HK1220142A1 (en) 2017-04-28
LT3549599T (lt) 2023-11-10
MX2016002166A (es) 2016-06-23
PE20160528A1 (es) 2016-05-21
KR20160044018A (ko) 2016-04-22
PH12016500275B1 (en) 2019-11-29
PE20201067A1 (es) 2020-10-19
HRP20231264T1 (hr) 2024-02-02
ZA201601437B (en) 2018-08-29
JP7195237B2 (ja) 2022-12-23
SI3549599T1 (sl) 2023-12-29
SMT201900471T1 (it) 2019-09-09
AU2014314304B2 (en) 2019-12-05
PL3038643T3 (pl) 2019-11-29
HRP20191051T1 (hr) 2019-09-06
WO2015028455A1 (fr) 2015-03-05
SG11201601151PA (en) 2016-03-30
PT3549599T (pt) 2023-11-21
TWI531582B (zh) 2016-05-01
ES2733735T3 (es) 2019-12-02
JP2016529266A (ja) 2016-09-23
HUE064437T2 (hu) 2024-03-28
EA036255B1 (ru) 2020-10-20
HUE045672T2 (hu) 2020-01-28
JP6632075B2 (ja) 2020-01-15
CA2922240C (fr) 2023-09-05
DK3549599T3 (en) 2023-10-30
US10421814B2 (en) 2019-09-24
IL244043A0 (en) 2016-04-21
GB201315487D0 (en) 2013-10-16
FI3549599T3 (fi) 2023-10-31
EP3549599B1 (fr) 2023-09-06
EP3549599A1 (fr) 2019-10-09
MY172484A (en) 2019-11-26
IL244043B (en) 2021-01-31
US20180162947A1 (en) 2018-06-14
DK3038643T3 (da) 2019-06-24
TW201512221A (zh) 2015-04-01
AU2014314304A1 (en) 2016-03-17
US20160200821A1 (en) 2016-07-14
TN2016000067A1 (en) 2017-07-05
US9908939B2 (en) 2018-03-06
CN112321711A (zh) 2021-02-05
SI3038643T1 (sl) 2019-08-30
BR112016004324A2 (pt) 2017-10-24
EP4282881A3 (fr) 2024-02-21
RS59019B1 (sr) 2019-08-30
CN105658236B (zh) 2021-03-19
UA118354C2 (uk) 2019-01-10
CY1121964T1 (el) 2020-10-14
PH12016500275A1 (en) 2016-05-02
EP3038643B1 (fr) 2019-05-01
MA38930A1 (fr) 2017-12-29
JP2022002523A (ja) 2022-01-11
EP3038643A1 (fr) 2016-07-06
EP4282881A2 (fr) 2023-11-29
CN112321711B (zh) 2024-11-08
NZ717399A (en) 2021-12-24
SMT202300409T1 (it) 2024-01-10
UY35718A (es) 2015-03-27
CN105658236A (zh) 2016-06-08
EA201690503A1 (ru) 2016-06-30
BR112016004324B1 (pt) 2024-01-16
ES2965207T3 (es) 2024-04-11
CL2016000438A1 (es) 2016-11-11
KR102303130B1 (ko) 2021-09-16

Similar Documents

Publication Publication Date Title
MA44922A1 (fr) Anticorps
MA37619A1 (fr) Anticorps anti-fcrn
MA39096B1 (fr) Anticorps spécifiques à fcrn
EA201892774A1 (ru) Антитела
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
MA38478A1 (fr) Anticorps anti-pac1 humains
EA202092589A2 (ru) Cxcr2-связывающие полипептиды
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
EA201270761A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
MA38400A1 (fr) Molécules fc bispécifiques
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
JO3623B1 (ar) البروتينات المرتبطة بمولد المستضاد st2
HK1210792A1 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
MA37407B1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
MX384222B (es) Matriz de cromatografia de afinidad.
MA44593A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
EP4375297A3 (fr) Anticorps contre le facteur c2b du complément humain et procédés d'utilisation
EA201591898A1 (ru) Антитела, направленные на m-csf